X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Sputnik V (Gam-COVID-Vac), shows significantly smaller (2.6 times) reduction of virus-neutralizing activity against Omicron as compared to the reference Wuhan variant than Pfizer vaccine (8.1-fold reduction for Sputnik V in contrast to 21.4-fold reduction for Pfizer vaccine).
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Russian Direct Investment Fund
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2022
Details:
The trial with involvement of 6000 participants would help to further investigate whether single-dose “Sputnik Light” vaccine could be a good choice for revaccination providing effective protection from SARS-CoV-2 infection in persons with pre-existing immunity.
Lead Product(s): rAd26
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik Light
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2021
Details:
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V, the world’s first registered vaccine against coronavirus.
Lead Product(s): rAd26
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik Light
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2021
Details:
Sputnik V vaccine demonstrated efficacy of 97.6%, based on the analysis of data on the infection rate of coronavirus among those in Russia vaccinated with both components of Sputnik V.
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2021
Details:
These study indicate that Sputnik V triggers the production of antibodies and immune cells that target the SARS-CoV-2 coronavirus and may help protect against COVID-19.
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2021
Details:
In an interim analysis of a Phase III clinical trial, Sputnik V showed strong efficacy, immunogenicity and safety results. Efficacy of Sputnik V against COVID-19 was reported at 91.6%.
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: ApprovedProduct Type: Vaccine
Recipient: Dr. Reddy\'s Laboratories
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2021
Details:
Abu Dhabi has started Phase III clinical trials of Russia’s Sputnik V COVID-19 vaccine amid a surge in infections in the United Arab Emirates. Two doses of the vaccine will be given, 20 days apart, to volunteers.
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
Details:
The Sputnik vaccine is being developed by Moscow's Gamaleya Research Institute and marketed by the Russian Direct Investment Fund (RDIF). Brazilian partner Uniao Quimica, a pharmaceutical company, entered the request with Anvisa.
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 30, 2020
Details:
Registering the Sputnik V vaccine based on the data from clinical trials in Russia confirms ANMAT’s high confidence in Russian regulatory standards.
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: ApprovedProduct Type: Vaccine
Recipient: Russian Direct Investment Fund
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2020
Details:
The Russian Direct Investment Fund (RDIF) has confirmed efficacy of over 90% for the Sputnik V vaccine. The Sputnik V vaccine efficacy against severe cases of coronavirus was 100%.
Lead Product(s): Gam-COVID-Vac
Therapeutic Area: Infections and Infectious Diseases Product Name: Sputnik V
Highest Development Status: ApprovedProduct Type: Vaccine
Recipient: Russian Direct Investment Fund
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
